Watch TELO. Know when insiders buy.
One email the day a filing lands. Free.
TELO
Telomir Pharmaceuticals, Inc.
1.22
−0.01 −1.22%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · shorts 48
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $83.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$5.9MNET CASH —52W 0.92 – 1.93SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | — | −$1.7M | — | -0.79 | −$1M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | — | −$991K | — | -0.03 | −$1.8M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | — | −$2.1M | — | -0.06 | −$1.2M | — | — | Mar 17 |
| Q3 2025 · Sep 30 | — | — | — | — | −$1.1M | — | -0.03 | −$927K | — | — | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | — | −$5.1M | — | -0.17 | −$696K | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | $2.2M | −$2.2M | — | -0.07 | −$863K | — | — | May 14 |
| Q4 2024 · Dec 31derived | — | — | — | — | −$2.9M | — | -0.10 | −$606K | — | — | Mar 17 |
| Q3 2024 · Sep 30 | — | — | — | — | −$6M | — | -0.20 | −$1M | — | — | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | — | −$1.4M | — | 0.05 | −$1.5M | — | — | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | $1.9M | −$6.3M | — | -0.23 | −$1.9M | — | — | Nov 10 |
| Q4 2023 · Dec 31 | — | — | — | — | −$9.3M | — | 0.62 | −$1.1M | — | — | Feb 4 |
| Q3 2023 · Sep 30 | — | — | — | — | −$1.7M | — | -0.06 | −$2M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | — | −$10.4M | — | -0.33 | −$3.7M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | — | −$16.5M | — | -0.56 | −$5.1M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | — | −$13.1M | — | 0.48 | −$3.9M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | — | −$854K | — | -0.03 | −$469K | — | — | — | — |
Every number comes from Telomir Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.